drugset / Trial / NCT07489651
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Timeline
- Start
- 2026-04-20
- Primary completion
- 2027-02
- Completion
- 2027-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | RE104 | Unknown | 30 mg | Subcutaneous |